- Full text PDF available (0)
- This year (5)
- Last 5 years (42)
- Last 10 years (46)
Journals and Conferences
8503Background: Avelumab* is a fully human anti-PD-L1 IgG1 antibody under clinical investigation in multiple cancers. We report safety and clinical activity of avelumab in patients (pts) with unres...
4071Background: Durvalumab, an anti-PD-L1 mAb, has shown early and durable clinical activity with manageable safety in an ongoing Phase 1/2, multicenter, open-label study in pts with advanced solid...
BackgroundOver the last several years, attempts have been made to use the tumoricidal effects of tumor necrosis factor (TNF)-α to treat cancer. Many of these studies demonstrated dose-limiting… (More)
4000 Background: Local and systemic inflammation (INFL) are hallmarks of cancer, including PC, that adversely impact prognosis. Given the role of JAK-STAT signaling in cancer INFL, the efficacy and… (More)
3531 Background: Perifosine (P), a synthetic alkylphospholipid, inhibits or modifies signal transduction pathways including AKT, MAPK and JNK. We previously reported initial results of a phase II… (More)
8056 Background: Belagenpumatucel-L (Lucanix) is a therapeutic vaccine comprised of 4 TGF-β2 antisense gene-modified, irradiated, allogeneic NSCLC cell lines. Methods: The trial enrolled patients (...
9074 Background: T-VEC is an HSV-1 derived oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and enhance systemic antitumor immune responses. We describe factors… (More)
TPS8576Background: Mesothelioma is a rare but aggressive cancer with a poor prognosis. Anetumab ravtansine (BAY 94-9343) is a novel fully human anti-mesothelin IgG1 antibody conjugated to the mytan...
166Background: Avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, is approved for treatment of metastatic Merkel cell carcinoma (US and EU) and advanced urothelial carcinoma progressed on… (More)
8517Background: Treatment options for ED-SCLC are limited, with standard first-line platinum and etoposide and second-line topotecan having limited clinical activity. Beyond these agents, no approv...